Analysis Inovio’s $80 Million Judgment and FDA Nod Share One Weakness: Neither Is Cash Yet
Inovio Pharmaceuticals closed out last week with two headline wins — a landmark court judgment and its first-ever FDA approval — but the company’s own cautionary language, and a pair...